Table 1.
Patient and tumor characteristics before SBRT.
| Category | Variables | 29 patients/30 tumors |
|---|---|---|
| Age, years | Median, IQR, range | 71, 64–77, 49–87 |
| Sex | Male/female | 22(76%)/7(24%) |
| ECOG Performance Status | 0/1/2/ | 21(72%)/7(24%)/1(3%) |
| Charlson comorbidity index | 0/1/2/3/4–5 | 3(10%)/10(34%)/8(28%)/ 4(14%)/4(14%) |
| Collagen disease | Yes/No | 2(7%)/27(93%) |
| SLE/Scleroderma | 1/1 | |
| Administration of antithrombotic drugs | Yes/No | 14(48%)/15(52%) |
| History of radical nephrectomy for kidney cancer | Yes/No | 3(10%)/26(90%) |
| Creatinine before SBRT, mg/dL | Median, IQR, range | 1.18, 0.80–2.04, 0.50–8.68 |
| Excluding HD patients (n = 27) | Median, IQR, range | 0.92, 0.70–1.38, 0.50–2.18 |
| HD before SBRT | Yes/No | 5(17%)/24(83%) |
| Operability | Operable/Inoperable/ Undecidable | 8(28%)/19(66%)/2(7%) |
| Reasons for choosing SBRT | Comorbidities/Renal function/Refusal of surgery | 20(69%)/4(14%)/5(17%) |
| Implantation of fiducial markers | Yes/No | 19(65%)/10(34%) |
| Maximum tumor diameter, mm, n = 30 | Median, IQR, range | 26, 22–33, 9–47 |
| T or rT stage, n = 30 | T1a/rT1a/T1b | 23(77%)/4(13%)/3(10%) |
| N stage | N0 | 29 (100%) |
| Location of the tumor, n = 30 | Right upper/mid/lower pole | 6(20%)/8(27%)/2(7%) |
| Left upper/mid/lower pole | 5(17%)/3(10%)/6(20%) |
Abbreviations: SBRT, stereotactic body radiotherapy; IQR, interquartile range; ECOG, Eastern Cooperative Oncology Group; SLE, systemic lupus erythematosus; HD, hemodialysis; rT, recurrent T.